Dr. Abbey Presented National Webinar on Treatment of Patients with Diabetic Macular Edema and 20/50 or Worse Vision
On Monday, September 19, 2022, Texas Retina Associates’ Ashkan M. Abbey, MD, delivered a webinar titled, “Does Treatment Selection Matter in Patients with Diabetic Macular Edema and 20/50 or Worse Vision?” Dr. Abbey discussed
read more
Texas Retina Associates First in the Country to Dose a Patient in the DAVIO 2 Clinical Trial
Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular
read more
Dr. Abbey and Dr. Williams Co-authored Article Published in Ophthalmology on the Influence of Face Mask Use on Endophthalmitis Risk After Eye Injections
Texas Retina Associates’ Ashkan Abbey, MD, and Patrick D. Williams, MD, co-authored a recently published article titled “The Influence of Universal Face Mask Use on Endophthalmitis Risk After Intravitreal Anti-VEGF Injections During
read more
Ashkan Abbey, MD, Publishes Article Summarizing Highlights from American Academy of Ophthalmology Retina 2019 Subspecialty Day
Texas Retina Associates’ Ashkan Abbey, MD, recently published an article in the current issue of Retina Specialist that summarized the findings of five compelling clinical trial presentations from the American Academy of
read more